29 July 2026

ASX RELEASE

QUARTERLY ACTIVITIES AND CASH FLOW REPORTS – June 2026

Key Highlights from the Quarter

- **ACCENT Trial:** Mature ACCENT trial data presented at the prestigious AACR meeting demonstrated favourable safety and encouraging efficacy for narmafotinib in metastatic pancreatic cancer, with improved activity across all measures than chemotherapy alone.
- **Phase 2b Pancreatic Cancer Study:** Initiated a Phase 2b study evaluating daily dosing of narmafotinib in combination with gemcitabine and Abraxane® in advanced pancreatic cancer, following FDA feedback and as the first stage of a planned registrational program, with enrolment expected to commence in Q4 CY2026.
- **PRROSE Ovarian Cancer Trial:** Partnered with ANZGOG to launch the PRROSE trial, evaluating narmafotinib in combination with standard chemotherapy in high-grade serous ovarian cancer, expanding the clinical development of the Company's FAK inhibitor program into a second oncology indication.
- **Board Renewal and Leadership Transition:** Implemented Board succession plans with Ms Jane Bell AM appointed Chair effective 30 June 2026, following Dr Warwick Tong's retirement as Chair and transition to Non-Executive Director, and further strengthened the Board with the appointment of experienced biopharmaceutical executive Brett Carter as a Non-Executive Director.
- **Intellectual Property Expansion:** Published a new patent application covering novel FAK inhibitors, extending potential intellectual property protection through to 2046 and further strengthening the Company's pipeline and long-term commercial opportunities.
- **Financial Position:** Amplia finished the June 2026 quarter with a cash position of A$24.0 million.

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), a company developing new approaches for the treatment for cancer and fibrosis, is pleased to announce further progress across its small molecule, focal adhesion kinase (FAK) inhibitor

ABN 16 165 160 841

+61 (0) 3 9123 1140 | info@ampliatx.com

Level 5, 90 William Street, Melbourne VIC 3000 Australia

www.ampliatx.com

program and the release of its Appendix 4C Cash Flow Report (attached) for the quarter ending 30 June 2026.

Operations Update

In April, the Company announced that mature data from its ACCENT trial had been presented in an oral presentation at the prestigious annual meeting of the American Association for Cancer Research, highlighting the strong clinical potential of its best-in-class FAK inhibitor, narmafotinib, in combination with standard chemotherapy for metastatic pancreatic cancer. The updated analysis showed a manageable safety profile with no significant additional toxicity, an 8% complete response rate (5 of 64 patients) compared with just 0.2% for chemotherapy alone, an overall response rate of 36% (42% including unconfirmed responses), a disease control rate of 70% versus 50% for chemotherapy alone, and improvements of more than two months in both median overall survival (11.1 months) and progression-free survival (7.7 months). The data also demonstrated a trend toward improved survival among patients achieving better treatment responses, with efficacy exceeding chemotherapy alone across all measures despite narmafotinib being administered for only 12 days of each 28-day cycle. Based on its favourable tolerability profile, future studies will evaluate daily dosing, which may further enhance clinical outcomes.

In May the Company reported that it had initiated a Phase 2b study of narmafotinib in advanced pancreatic cancer to evaluate daily dosing of narmafotinib in combination with the chemotherapies gemcitabine and Abraxane®, following FDA feedback and as the first stage of a planned registrational study. The trial will enrol 12 newly diagnosed patients across two dose cohorts at 3-4 Australian sites, assessing safety, tolerability, pharmacokinetics, efficacy, biomarkers and fibrosis, with enrolment expected to commence early in the fourth quarter of 2026 and with critical safety data available in the second quarter of 2027. This clinical study has been accelerated through the redeployment of resources from the AMPLICITY trial where further recruitment was halted earlier in the year. Including the safety and pharmacokinetic data from this trial is expected to strengthen the Company's planned registrational submission to the FDA in Q2 2027.

Amplia and the Australia New Zealand Gynaecological Oncology Group (ANZGOG) disclosed in May that they had partnered to launch the PRROSE trial. This trial is an investigator-initiated study led by Dr Gwo Yaw Ho of Monash Health, to evaluate narmafotinib in combination with standard chemotherapy for patients with high-grade serous ovarian cancer who have responded poorly to initial chemotherapy treatment. The trial, which will enrol approximately 20 patients across Australia and New Zealand, aims to assess safety while exploring whether the addition of narmafotinib can improve response rates and increase the number of patients eligible for potentially life-extending surgical resection, addressing a significant unmet medical need. The study will also incorporate extensive biomarker analyses to better understand narmafotinib's mechanism of action in this indication. There is a compelling biological rationale for FAK inhibitors in ovarian cancer and the Company has preclinical data further supporting the clinical potential in this indication. The trial represents an important opportunity to improve outcomes for up to 20% of patients with limited treatment options, while also broadening the clinical utility of the Company's FAK inhibitor program. Lead investigator Dr Gwo Yaw Ho highlighted ANZGOG's strong collaborative network and track record of delivering rigorous, potentially practice-changing clinical research, noting the trial's commitment to translating promising science into meaningful evidence that could inform future treatment options for women with ovarian cancer.

Amplia announced Board leadership changes as part of its Board renewal and succession strategy, with Dr Warwick Tong retiring as Chairman on 30 June 2026 after serving as a Director

since 2018, while remaining on the Board as a Non-Executive Director. Independent Non-Executive Director Ms Jane Bell AM, who joined the Board in 2021 has been unanimously appointed Chair effective 30 June 2026. Dr Tong said it had been "a great privilege" to help shape the Company over the past eight years and that, given the success of recent clinical trials and growing interest in Amplia's portfolio, it was an appropriate time to implement Board changes, expressing confidence that Ms Bell would bring valuable life sciences experience and strategic insight to the role. Ms Bell thanked Dr Tong for his "exemplary leadership, expertise and dedicated service," noting that his contributions to drug discovery, development, partnerships and corporate strategy had been integral to Amplia's progress, and said she looked forward to leading the Board and executing the Company's long-term strategy for shareholders.

In early July the Company announced the appointment of experienced biopharmaceutical executive Brett Carter as a Non-Executive Director further strengthening the Board as the Company advances narmafotinib into later-stage clinical development. Mr Carter brings more than 25 years of global experience spanning oncology drug development, corporate strategy and business development, including 8 years with GSK's global corporate transactions team, where he led major licensing, acquisition, investment and divestment deals across Europe, Asia and the United States. He also served as CEO of the Cancer Therapeutics CRC, where Amplia's drug assets were originally discovered.

During the quarter a new patent application from the Company, covering chemically novel inhibitors of focal adhesion kinase (FAK), was published. This patent application, if granted, further strengthens the Company's intellectual property portfolio and potentially provides protection for these new compounds and their therapeutic use through to 2046. The application expands Amplia's existing FAK franchise, which already includes its lead clinical-stage candidate narmafotinib and preclinical candidate AMP886, by introducing additional compounds closely related to narmafotinib that demonstrate potent and selective FAK inhibition. These novel molecules broaden the Company's development pipeline, create opportunities for future development across additional disease indications, and enhance the long-term commercial value of its assets.

Financial update

Amplia finished the June 2026 quarter with a cash position of $24.0 million (March 2026: $27.9 million). During the quarter, the Company had net operating cash outflows of $3.9 million in relation to operating activities (March 2026: $3.5 million inflows). Operating cashflows included:

- Outflows of $1.1 million for staff and administration/corporate costs; and
- Outflows of $3.0 million for research and development costs, which primarily related to trial costs, Contract Research Organisation (CRO), manufacturing and other CMC related costs incurred in relation to the ACCENT Phase 2 clinical trial.

Payments to Related Entities

In accordance with Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of the Appendix 4C incorporates directors' fees, salaries and superannuation. Total payments made for the quarter equals $112,500 and relate to payments to the CEO/Managing Director in line with the employment contract and payments to the Non-Executive Directors.

- End -

For Further Information

Dr. Christopher Burns

CEO and Managing Director

Chris@ampliatx.com

www.ampliatx.com

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit **www.ampliatx.com** and follow Amplia on X (@ampliatx) and LinkedIn.

About Narmafotinib

Narmafotinib (AMP945) is the company's best-in-class inhibitor of FAK, a protein over-expressed in multiple cancers and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently being investigated in the ACCENT trial in advanced pancreatic cancer where it is dosed in combination with the chemotherapies gemcitabine and nab-paclitaxel (Abraxane®) in first-line patients. The trial has achieved its desired outcome in achieving a response rate of 36%, superior to chemotherapy alone as reported for the benchmark MPACT study. A median Overall Survival (mOS) of 11.1 months has been reported along with an unprecedented complete response rate of 7.8%. A second trial (AMPLICITY) is being run at sites in Australia investigating the combination of narmafotinib with the chemotherapy mFOLFIRINOX in advanced pancreatic cancer patients, and a third trial in ovarian cancer (the PRROSE trial) is scheduled to begin recruiting later this year.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

AMPLIA THERAPEUTICS LIMITED

ABN	**Quarter ended ("current quarter")**
16 165 160 841	30 June 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) research and development	(2,951)	(2,951)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs	(461)	(461)
	(f) administration and corporate costs	(676)	(676)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	222	222
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (bank guarantee and GST)	1	1
1.9	**Net cash from / (used in) operating activities**	**(3,865)**	**(3,865)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(13)	(13)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (bank guarantee and security deposit)	-	-
2.6	**Net cash from / (used in) investing activities**	**(13)**	**(13)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (repayment of lease liability)	(27)	(27)
3.10	**Net cash from / (used in) financing activities**	**(27)**	**(27)**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	27,854	27,854
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,865)	(3,865)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(13)	(13)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(27)	(27)
4.5	Effect of movement in exchange rates on cash held	35	35
4.6	**Cash and cash equivalents at end of period**	**23,984**	**23,984**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	2,386	1,472
5.2	Call deposits	21,598	26,382
5.3	Bank overdrafts	-	-
5.4	Other (provide details)		
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**23,984**	**27,854**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	112
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

The amount at 6.1 includes Director fees and salary (including superannuation) for the CEO and Managing Director and Non-Executive Directors.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	**-**	**-**

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

N/A

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(3,865)
8.2	Cash and cash equivalents at quarter end (item 4.6)	23,984
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	23,984
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**6.2**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

29 July 2026

Date: .....

The Board of Directors

Authorised by: .....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.